QQ客服 官方微博 反馈留言

	Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
	Yuan, Peng; Shentu, Jianzhong; Xu, Jianming; Burke, Wendy; Hsu, Kate; Learoyd, Maria; Zhu, Min; Xu, Binghe
	2019
卷号	83期号:5页码:963-974
关键词	Chinese patients Olaparib Paclitaxel PARP inhibitor Pharmacokinetics Safety
ISSN号	0344-5704
DOI	10.1007/s00280-019-03799-1
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6343038
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Yuan, Peng,Shentu, Jianzhong,Xu, Jianming,et al. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours[J],2019,83(5):963-974.
APA	Yuan, Peng.,Shentu, Jianzhong.,Xu, Jianming.,Burke, Wendy.,Hsu, Kate.,...&Xu, Binghe.(2019).Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.,83(5),963-974.
MLA	Yuan, Peng,et al."Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours".83.5(2019):963-974.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。